Premium
The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects.
Author(s) -
Salmonson T,
Danielson BG,
Wikstrom B
Publication year - 1990
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1990.tb03692.x
Subject(s) - erythropoietin , pharmacokinetics , bioavailability , volume of distribution , medicine , pharmacology , half life , subcutaneous injection , recombinant dna , distribution (mathematics) , chemistry , biochemistry , gene , mathematical analysis , mathematics
1. The pharmacokinetics of recombinant erythropoietin, r‐Epo, were evaluated after intravenous and subcutaneous administration of 50 u kg‐ 1 to six healthy male volunteers. 2. The calculated mean values (+/− s.d.) for volume of distribution at steady state and clearance after an i.v. dose were 76 (+/− 33) ml kg‐1 and 12 (+/− 3) ml h‐1 kg‐1, respectively. 3. Serum concentrations of r‐Epo peaked at 13 (+/− 6) h after the s.c. dose and the bioavailability over 72 h was 36 (+/− 23)%. The mean residence time and half‐life of erythropoietin were 6.2 (+/− 1.0) and 4.5 (+/− 0.9) h respectively after i.v. and 46 (+/− 18) and 25 (+/− 12) h after s.c. administration. 4. The results demonstrate the possibility of changing the profile of the concentration‐time curve by changing the mode of administration of r‐Epo, with implications for the time‐course of clinical response.